Vext Science Inc (VEXT)

Vext Opens Sixth Ohio Dispensary in FairfieldJune 1, 2026 6:14 PM
NewsfileA high-visibility location on one of the area's busiest retail corridors, anchored by neighboring Jungle Jim's International Market - expected to drive durable store-level performance.Vancouver, British Columbia--(Newsfile Corp. - June 1, 2026) - Vext Science, Inc. (CSE: VEXT) (OTCQX: VEXTF) ("Vext" or the "Company"), a U.S.-based cannabis operator with operations in Arizona and Ohio, today announced that its Herbal Wellness Center dispensary in Fairfield, Ohio (the "Dispensary") has commenced operations and is now open to the public for both medical and adult-use sales. All currency references used in this news release are in U.S. currency unless otherwise noted.The Dispensary is Vext's sixth operating dispensary in Ohio. The approximately 3,825-square-foot store is located in Fairfield, a northern suburb of Cincinnati, just off Route 4, a high-traffic commercial corridor. It sits adjacent to Jungle Jim's International Market, a major regional retail attraction, within a broader retail node that includes national retailers and a large fitness center, a setting that supports strong and consistent consumer traffic. The Company expects Fairfield to become a meaningful contributor to revenue and cash flow as it stabilizes.Eric Offenberger, CEO of Vext commented, "Opening Fairfield is an important milestone in our disciplined retail build-out. We've secured a strong, high-visibility position there, next to one of the region's biggest retail draws. Our strategy in Ohio is straightforward and a continuation of our long-held playbook - open the right stores in the right locations, supply them from our own highly efficient cultivation operation, and convert that into cash. Every store we add makes the proven model stronger and brings us one step closer to the state's eight-store cap."Vext's six Ohio dispensaries are supported by its Tier One cultivation and manufacturing facilities in Jackson, Ohio. A seventh dispensary, in Columbus, holds a dual-use provisional license, is under construction and is expected to open in the fourth quarter of 2026. A third dual-use dispensary under the Ohio Division of Cannabis Control 10(B) program remains under evaluation, which would complete the Company's build-out to the state's eight-store cap.For more details, visit Vext's investor website or contact the IR team at investors@vextscience.com.About Vext Science, Inc.Vext Science, Inc. is a U.S.-based cannabis operator with operations in Arizona and Ohio. Based out of Arizona, Vext owns and operates state-of-the-art cultivation facilities, fully built-out manufacturing facilities as well as dispensaries in both Arizona and Ohio. The Company manufactures Vapen™, one of the leading THC concentrates, edibles, and distillate cartridge brands in Arizona. Its selection of award-winning products are created with Vext's in-house, high-quality flower and distributed across Arizona and Ohio. Vext's leadership team brings a proven track record of building and operating profitable multi-state operations. The Company's primary focus is to continue growing in its core states of Arizona and Ohio, bringing together cutting-edge science, manufacturing, and marketing to provide a reliable and valuable customer experience while generating shareholder value. Vext Science, Inc. is listed on the Canadian Securities Exchange under the symbol VEXT and trades on the OTCQX market under the symbol VEXTF. Learn more at www.vextscience.com and connect with Vext on Twitter/X and LinkedIn.Forward-Looking StatementsStatements in this news release that are forward-looking statements are subject to various risks and uncertainties concerning the specific factors disclosed here and elsewhere in Vext's periodic filings with Canadian securities regulators. When used in this news release, words such as "will, anticipate, could, plan, estimate, expect, intend, may, potentially, believe, should," and similar expressions, are forward-looking statements.Forward-looking statements may include, without limitation, statements regarding future developments and the business and operations of Vext, including but not limited to the Company's expansion in Ohio and the anticipated results therefrom, the expected performance and ramp of the Fairfield dispensary, the receipt of applicable regulatory approvals, and the development and opening of additional dispensaries in Ohio, including the Company's progress toward the state's eight-store license cap, all of which are subject to the risk factors contained in Vext's continuous disclosure documents filed on SEDAR+ at www.sedarplus.ca. The material assumptions underlying the foregoing forward-looking statements include, without limitation: receipt of applicable regulatory approvals in the ordinary course; no material adverse change in applicable laws, including Ohio cannabis laws; the ability of the Company to fund its operations and capital requirements, including the Columbus dispensary construction; no material construction delays or cost overruns with respect to the Columbus dispensary; and stable or improving consumer demand for cannabis in Ohio.Although Vext has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking statements, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended, including, but not limited to: dependence on obtaining regulatory approvals; being engaged in activities currently considered illegal under U.S. Federal laws; change in laws; reliance on management; requirements for additional financing; competition; hindered market growth and state adoption due to inconsistent public opinion and perception of the medical-use and adult-use marijuana industry; and regulatory or political change.There can be no assurance that such information will prove to be accurate or that management's expectations or estimates of future developments, circumstances or results will materialize. Because of these risks and uncertainties, the results or events predicted in these forward-looking statements may differ materially from actual results or events.Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release are made as of the date of this release. Vext disclaims any intention or obligation to update or revise such information, except as required by applicable law, and Vext does not assume any liability for disclosure relating to any other company mentioned herein.The Canadian Securities Exchange has not reviewed, approved or disapproved the content of this news release.Eric Offenberger
Chief Executive Officer
844-211-3725For further information:
Jonathan Ross, Vext Investor Relations
jon.ross @papaphilip-0178SOURCE: Vext Science, Inc.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/299745 Original: Vext Opens Sixth Ohio Dispensary in Fairfield

Vext Reports Q1 2026 Financial Results; Adjusted EBITDA up 73% Sequentially to $3.6 Million as Ohio Platform ScalesMay 21, 2026 6:30 AM
NewsfileRevenue of $12.2 million, up 5.2% year-over-year; gross profit more than doubled to $5.5 million (45.4% margin), and net loss narrowed 73.2% to $(0.9) million.Operating cash flow of $1.6 million and cash position of $5.5 million at quarter-end.Ohio revenue of $8.2 million, up 34% year-over-year across five operating dispensaries, with improving cultivation yields; Arizona repositioning on track with the Eloy cultivation exit underway.Vancouver, British Columbia--(Newsfile Corp. - May 21, 2026) - Vext Science, Inc. (CSE: VEXT) (OTCQX: VEXTF) ("Vext" or the "Company"), a U.S.-based cannabis operator with operations in Arizona and Ohio, today reported its financial results for the period ended March 31, 2026. All currency references used in this news release are in U.S. currency unless otherwise noted.Summary Financial Results (in thousands of US dollars)

Q1 2026

Q4 2025

Q1 2025
Sales$12,160
$13,728
$11,561
EBITDA*$4,146
$(3,035)$1,018
Adjusted EBITDA*$3,559
$2,059
$3,425
Adjusted EBITDA Margin (%)*
29%

15%

30%
Net cash provided by operating activities$1,615
$3,196
$3,082
Cash Flow Margin (%)*
13%

23%

27%
 * See "Non-IFRS Financial Measures" below for more information regarding's Vext's use of non-IFRS financial measures and other reconciliations.Management Commentary Eric Offenberger, CEO of Vext commented, "Q1 was a strong quarter for Vext. Gross profit more than doubled to $5.5 million, and Adjusted EBITDA was $3.6 million on 29% margins, up sharply from where we ended last year. Ohio drove the quarter. Revenue was up 34% to $8.2 million across five stores, and our cultivation is improving every quarter. The strategy we have been executing on is straightforward: build disciplined retail operations and match the upstream platform to the realities of each market."Mr. Offenberger continued, "In Ohio, where vertical integration and scale continue to create value, every store we add strengthens the model and supports improving cash flow generation. In Arizona, the cultivation exit is underway and remains on track to be completed by the end of the second quarter of 2026. The Arizona wholesale market is oversupplied, and prices have compressed to the point where our capital was better deployed elsewhere. What remains is the part of Arizona that has maintained economic viability: two dispensaries, light manufacturing, and the flexibility to source and price competitively. Between an Ohio platform that's scaling, and an Arizona business now right-sized for the market, we believe the business is well positioned to continue generating strong cash flow through 2026 and beyond."Q1 2026 Financial Results Conference CallThe Company will host a conference call and webcast today at 08:00 am ET to discuss the financial results for the first quarter of 2026.Date: May 21, 2026 | Time: 8:00 am ET
Participant Dial-in: 1-833-752-3966 or 1-647-849-3159
Replay Dial-in: 1-855-669-9658 or 1-412-317-0088
Conference ID: 10209351
Playback #: 9921417 (Expires on June 4, 2026)
Listen to webcast: https://www.gowebcasting.com/14724 For more details, visit Vext's investor website or contact the IR team at investors@vextscience.com. Uncertain Tax Position and Income Tax PayableAs at March 31, 2026, the Company has recognized an uncertain tax position ("UTP") liability of $10.6 million, compared to $8.1 million as of December 31, 2025, related to uncertain tax treatments regarding the deductibility of certain costs. The liability has been measured using the "most likely amount" method based on legal advice. The ultimate outcome may differ from the liability recognized; however, the range of possible outcomes is not expected to be material beyond the amount provided. As at March 31, 2026, the Company reclassified $2.5 million of income tax payable to uncertain tax position on the condensed consolidated interim statement of financial position, reflecting progress in finalizing its tax filing position for the year ended December 31, 2025. The reclassification reflects the Company's best estimate of its final tax filing position and remains subject to change pending finalization of the 2025 tax returns.On April 23, 2026, the United States Drug Enforcement Administration issued a final rule rescheduling certain state-licensed marijuana products to Schedule III (the "Rule"). The Rule includes a non-binding recommendation regarding potential retroactive tax treatment under Section 280E. If enacted, this would materially reduce the uncertain tax position. However, as a non-adjusting event under IAS 10, Events After the Reporting Period, no adjustment has been made to the March 31, 2026 financial statements. The Company will evaluate the impact, if any, in future reporting periods.For additional details, please refer to the Company's condensed consolidated interim financial statements (including the notes thereto) and MD&A filed on SEDAR+.Non-IFRS Financial MeasuresThis news release contains certain "non-IFRS financial measures" (equivalent to "non-GAAP financial measures", as such term is defined in National Instrument 52-112 - Non-GAAP and Other Financial Measures Disclosure ("NI 52-112")), "non-IFRS ratios" (equivalent to "non-GAAP ratios", as such term is defined in NI 52-112), or "supplementary financial measures" (as such term is defined in NI 52-112), which are described in further detail below. These financial measures do not have a standardized definition under IFRS, nor are they calculated or presented in accordance with IFRS and may not be comparable to similar measures presented by other companies. The Company has provided these financial measures as supplemental information and in addition to the financial measures that are calculated and presented in accordance with IFRS. The Company believes that these supplemental financial measures provide a valuable additional measure to use when analyzing the operating performance of the business. These supplemental financial measures should not be considered superior to, as a substitute for or as an alternative to, and should only be considered in conjunction with, the IFRS financial measures presented herein.The Company defines Cash Flow Margin by dividing Net cash provided by operating activities by Sales. The Company believes that this measure provides investors with insight into the Company's ability to generate cash from its revenue base. It is used by the Company to assess operating efficiency and liquidity performance without the impact of financing or investing activities. The calculation of Cash Flow Margin is as follows:

Q1 2026

Q4 2025

Q1 2025
Net cash provided by operating activities
(in thousands of US dollars)$1,615
$3,196
$3,082
Sales
(in thousands of US dollars)$12,160
$13,728
$11,561
Cash Flow Margin (%)
13%

23%

27%
 The Company defines EBITDA as earnings before interest, taxes, depreciation and amortization. The Company defines "Adjusted EBITDA" as net income (loss) from operations, as reported, before interest and tax, adjusted to exclude extraordinary items, non-recurring items, other non-cash items, including stock-based compensation expense, depreciation and amortization, foreign exchange and acquisition related costs, if applicable. The Company defines "Adjusted EBITDA Margin" as Adjusted EBITDA divided by Sales. The Company believes that these measures are useful financial metrics as they assist in determining the ability to generate cash from operations. Investors should be cautioned that EBITDA and Adjusted EBITDA should not be construed as an alternative to net earnings or cash flows as determined under IFRS. The reconciling items between net earnings, EBITDA, and Adjusted EBITDA are as follows:(in thousands of US dollars)
Q1 2026

Q4 2025

Q1 2025
Sales$12,160
$13,728
$11,561
Net Income after taxes
(892)
(10,557)
(3,334)Interest (Net)
810

1,998

832
Income Taxes
249

1,504

(223)Depreciation & Amortization
3,979

4,019

3,742
EBITDA
4,146

(3,035)
1,018
Share-based compensation
7

(6)
(24)Change in FV of debt
372

(514)
(153)Change in FV of Biological
(1,171)
903

1,679
Miscellaneous (income) expense
205

(309)
906
Goodwill and Intangible Impairment
-

5,020

-
Adjusted EBITDA$3,559
$2,059
$3,425
Adjusted EBITDA Margin (%)*
29.3%

15.0%

29.6%
 About Vext Science, Inc.Vext Science, Inc. is a U.S.-based cannabis operator with operations in Arizona and Ohio. Based out of Arizona, Vext owns and operates state-of-the-art cultivation facilities, fully built-out manufacturing facilities as well as dispensaries in both Arizona and Ohio. The Company manufactures Vapen™, one of the leading THC concentrates, edibles, and distillate cartridge brands in Arizona. Its selection of award-winning products are created with Vext's in-house, high-quality flower and distributed across Arizona and Ohio. Vext's leadership team brings a proven track record of building and operating profitable multi-state operations. The Company's primary focus is to continue growing in its core states of Arizona and Ohio, bringing together cutting-edge science, manufacturing, and marketing to provide a reliable and valuable customer experience while generating shareholder value. Vext Science, Inc. is listed on the Canadian Securities Exchange under the symbol VEXT and trades on the OTCQX market under the symbol VEXTF. Learn more at www.vextscience.com and connect with Vext on Twitter/X and LinkedIn.Forward-Looking Statements
Statements in this news release that are forward-looking statements are subject to various risks and uncertainties concerning the specific factors disclosed here and elsewhere in Vext's periodic filings with Canadian securities regulators. When used in this news release, words such as "will, could, plan, estimate, expect, intend, may, potential, believe, should," and similar expressions, are forward-looking statements.Forward-looking statements may include, without limitation, statements regarding future developments and the business and operations of Vext, including but not limited to the Company's expansion in Ohio, its optimization strategy in Arizona and the anticipated results therefrom, the potential change to the Company's UTP position, the sale of the Eloy facility and the use of proceeds from such sale, the receipt of applicable regulatory approvals and the opening of additional dispensaries in Ohio, all of which are subject to the risk factors contained in Vext's continuous disclosure documents filed on SEDAR+ at www.sedarplus.ca. Although Vext has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking statements, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended, including, but not limited to: dependence on obtaining regulatory approvals; being engaged in activities currently considered illegal under U.S. Federal laws; change in laws; reliance on management; requirements for additional financing; competition; hindered market growth and state adoption due to inconsistent public opinion and perception of the medical-use and adult-use marijuana industry; and regulatory or political change. There can be no assurance that such information will prove to be accurate or that management's expectations or estimates of future developments, circumstances or results will materialize. Because of these risks and uncertainties, the results or events predicted in these forward-looking statements may differ materially from actual results or events.Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release are made as of the date of this release. Vext disclaims any intention or obligation to update or revise such information, except as required by applicable law, and Vext does not assume any liability for disclosure relating to any other company mentioned herein.The Canadian Securities Exchange has not reviewed, approved or disapproved the content of this news release.Eric Offenberger
Chief Executive Officer
844-211-3725For further information:
Jonathan Ross, Vext Investor Relations
jon.ross @anajatwo-9851SOURCE: Vext Science, Inc.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/298269 Original: Vext Reports Q1 2026 Financial Results; Adjusted EBITDA up 73% Sequentially to $3.6 Million as Ohio Platform Scales

Vext Engages Zuanic & AssociatesMay 15, 2026 7:30 AM
NewsfileVancouver, British Columbia--(Newsfile Corp. - May 15, 2026) - Vext Science, Inc. (CSE: VEXT) (OTCQX: VEXTF) ("Vext" or the "Company") a U.S.-based cannabis operator with operations in Arizona and Ohio, today announced that it has entered into an investor relations agreement (the "Services Agreement") with Zuanic & Associates ("Zuanic").Pursuant to the Services Agreement, Zuanic will provide advisory, research and investor relations services to the Company over a twelve-month term, beginning on May 15, 2026, for a monthly cash fee not exceeding US$7,000. Such services may be delivered in a variety of different mediums through different platforms.Zuanic is a financial consulting and research advisory firm with an address at 971 US Highway 202 N, Suite A, Branchburg, New Jersey 08876, USA and can be contacted via e-mail at pablo.zuanic @captainmlw-1687. Zuanic is arm's length to the Company.For more details, visit Vext's investor website or contact the IR team at investors@vextscience.com. About Vext Science, Inc.Vext Science, Inc. is a U.S.-based cannabis operator with operations in Arizona and Ohio. Based out of Arizona, Vext owns and operates state-of-the-art cultivation facilities, fully built-out manufacturing facilities as well as dispensaries in both Arizona and Ohio. The Company manufactures Vapen™, one of the leading THC concentrates, edibles, and distillate cartridge brands in Arizona. Its selection of award-winning products are created with Vext's in-house, high-quality flower and distributed across Arizona and Ohio. Vext's leadership team brings a proven track record of building and operating profitable multi-state operations. The Company's primary focus is to continue growing in its core states of Arizona and Ohio, bringing together cutting-edge science, manufacturing, and marketing to provide a reliable and valuable customer experience while generating shareholder value. Vext Science, Inc. is listed on the Canadian Securities Exchange under the symbol VEXT and trades on the OTCQX market under the symbol VEXTF. Learn more at www.vextscience.com and connect with Vext on Twitter/X and LinkedIn.Forward-Looking Statements Statements in this news release that are forward-looking statements are subject to various risks and uncertainties concerning the specific factors disclosed here and elsewhere in Vext's periodic filings with Canadian securities regulators. When used in this news release, words such as "will, could, plan, estimate, expect, intend, may, potential, believe, should," and similar expressions, are forward-looking statements.Forward-looking statements may include, without limitation, statements related to the Services Agreement, including but not limited to the provision of investor relations activities thereunder and the extension thereof, and other statements regarding future developments and the business and operations of Vext, all of which are subject to the risk factors contained in Vext's continuous disclosure filed on SEDAR+ at www.sedarplus.ca. Although Vext has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking statements, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended, including, but not limited to: dependence on obtaining regulatory approvals; being engaged in activities currently considered illegal under U.S. Federal laws; change in laws; reliance on management; requirements for additional financing; competition; hindered market growth and state adoption due to inconsistent public opinion and perception of the medical-use and adult-use marijuana industry and; regulatory or political change.There can be no assurance that such information will prove to be accurate or that management's expectations or estimates of future developments, circumstances or results will materialize. Because of these risks and uncertainties, the results or events predicted in these forward-looking statements may differ materially from actual results or events.Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release are made as of the date of this release. Vext disclaims any intention or obligation to update or revise such information, except as required by applicable law, and Vext does not assume any liability for disclosure relating to any other company mentioned herein.The Canadian Securities Exchange has not reviewed, approved or disapproved the content of this news release.Eric Offenberger
Chief Executive Officer
844-211-3725For further information:
Jonathan Ross, Vext Investor Relations
jon.ross @anajatwo-9851SOURCE: Vext Science, Inc.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/297132 Original: Vext Engages Zuanic & Associates

Vext Announces Date for Q1 2026 Financial Results ReleaseMay 14, 2026 5:00 PM
NewsfileVancouver, British Columbia--(Newsfile Corp. - May 14, 2026) - Vext Science, Inc. (CSE: VEXT) (OTCQX: VEXTF) ("Vext" or the "Company") a U.S.-based cannabis operator in Arizona and Ohio, today announced that the Company expects to release its financial results for the period ended March 31, 2026, before market open on Thursday, May 21, 2026. The Company will host a conference call and webcast on the same day at 08:00 am ET to discuss the financial results for the first quarter of 2026.CONFERENCE CALL DETAILSDate: May 21, 2026 | Time: 8:00 am ET
Participant Dial-in: 1-833-752-3966 or 1-647-849-3159
Replay Dial-in: 1-855-669-9658 or 1-412-317-0088
Conference ID: 10209351
Playback #: 9921417 (Expires on June 4, 2026)
Listen to webcast: https://www.gowebcasting.com/14724 A replay of the conference call and webcast will be available on Vext's investor website following the conclusion of the call.For more details, visit Vext's investor website or contact the IR team at investors@vextscience.com. About Vext Science, Inc.
Vext Science, Inc. is a U.S.-based cannabis operator with operations in Arizona and Ohio. Vext owns and operates state-of-the-art cultivation facilities, fully built-out manufacturing facilities as well as dispensaries across its footprint. The Company manufactures Vapen™, one of the leading THC concentrates, edibles, and distillate cartridge brands in Arizona. Its selection of award-winning products are created with Vext's in-house, high-quality flower and distributed across its key markets. Vext's leadership team brings a proven track record of building and operating profitable multi-state operations. The Company's primary focus is to continue growing in its core states of Arizona and Ohio, bringing together cutting-edge science, manufacturing, and marketing to provide a reliable and valuable customer experience while generating shareholder value. Vext Science, Inc. is listed on the Canadian Securities Exchange under the symbol VEXT and trades on the OTCQX market under the symbol VEXTF. Learn more at www.vextscience.com and connect with Vext on Twitter/X and LinkedIn.Forward-Looking Statements
Statements in this news release that are forward-looking statements are subject to various risks and uncertainties concerning the specific factors disclosed here and elsewhere in Vext's periodic filings with Canadian securities regulators. When used in this news release, words such as "will", "could", "plan", "estimate", "expect", "intend", "may", "potential", "believe", "should", "positioned", and similar expressions, are forward-looking statements.Forward-looking statements may include, without limitation, statements regarding the expected filing date of the financial results, future developments and the business and operations of Vext, all of which are subject to the risk factors contained in Vext's continuous disclosure filed on SEDAR+ at www.sedarplus.ca. Although Vext has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking statements, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended, including, but not limited to: dependence on obtaining regulatory approvals; being engaged in activities currently considered illegal under U.S. Federal laws; change in laws; reliance on management; requirements for additional financing; competition; hindered market growth and state adoption due to inconsistent public opinion and perception of the medical-use and adult-use marijuana industry; and regulatory or political change. There can be no assurance that such information will prove to be accurate or that management's expectations or estimates of future developments, circumstances or results will materialize. Because of these risks and uncertainties, the results or events predicted in these forward-looking statements may differ materially from actual results or events.Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release are made as of the date of this release. Vext disclaims any intention or obligation to update or revise such information, except as required by applicable law, and Vext does not assume any liability for disclosure relating to any other company mentioned herein.The Canadian Securities Exchange has not reviewed, approved or disapproved the content of this news release.Eric Offenberger
Chief Executive Officer
844-211-3725For further information:
Jonathan Ross, Vext Investor Relations
jon.ross @anajatwo-9851SOURCE: Vext Science, Inc.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/297485 Original: Vext Announces Date for Q1 2026 Financial Results Release

Vext Reports Q4 and FY 2025; Fiscal 2025 Revenue up +43% to $51.4M, Operating Cash Flow up +256% to $11.7M as Ohio Retail ScalesApril 29, 2026 6:30 AM
NewsfileFiscal 2025 revenue of $51.4 million, up +43% YoY, with EBITDA* of $5 million and Adjusted EBITDA* of $10.9 million; net cash provided by operating activities of $11.7 million, up +256% (+$8.4 million) YoY. Margins expected to improve as newer Ohio retail locations ramp and the retail base continues to stabilize.Q4 2025 revenue of $13.7 million, up +35% YoY; Adjusted EBITDA* of $2.1 million and net cash provided by operating activities of $3.2 million. Reported Q4 EBITDA* of $(3) million reflects a $5.0 million non-cash impairment on one Columbus, Ohio dispensary.Expanded Ohio retail footprint to five operating locations. On track to reach the state dispensary license cap of eight by early 20271, positioning Vext to capture sustained growth from growing adult-use market in Ohio.Proactive optimization of Arizona operations underway, including the planned exit of cultivation at Eloy, reflecting disciplined capital allocation to enhance free cash flow and redeploy capital toward higher-return growth opportunities in Ohio.Vancouver, British Columbia--(Newsfile Corp. - April 29, 2026) - Vext Science, Inc. (CSE: VEXT) (OTCQX: VEXTF) ("Vext" or the "Company") a U.S.-based cannabis operator with operations in Arizona and Ohio, today reported its financial results for the period ended December 31, 2025. All currency references used in this news release are in U.S. currency unless otherwise noted.Summary Financial Results (in thousands of US dollars)

FY 2025

FY 2024

Q4 2025

Q3 2025

Q4 2024
Sales$51,367
$35,998
$13,728
$12,671
$10,194
EBITDA*$4,961
$(2,240)$(3,036)$1,785
$(2,047)Adjusted EBITDA*$10,930
$9,062
$2,058
$1,513
$3,238
Adjusted EBITDA Margin (%)*
21%

25%

15%

12%

32%
Net cash provided by operating activities$11,712
$3,289
$3,196
$1,259
$4,016
Cash Flow Margin (%)*
23%

9%

23%

10%

39%
 * See "Non-IFRS Financial Measures" below for more information regarding's Vext's use of non-IFRS financial measures and other reconciliations.Management Commentary Eric Offenberger, CEO of Vext commented, "2025 was a year of solid execution and meaningful transition for Vext. We delivered strong financial performance, with revenue increasing +43% to $51.4 million and operating cash flow increasing +256% to $11.7 million in Fiscal 2025, while expanding our Ohio retail footprint from two to five locations during the year. These results reflect the benefits of scaling our owned retail platform, particularly in Ohio, as growing volumes were able to drive operating leverage across a largely established cost base, supporting improved cash flow generation."I am pleased with our performance across both core markets. In Ohio, our stores are already standing out, with most performing above the state average, and we are now focused on bringing our remaining three dispensaries online while expanding cultivation. In Arizona, despite a tougher pricing environment, our teams stayed disciplined, supported by strong cultivation yields. As announced last month, we are transitioning to a lean, retail-first model in Arizona - exiting cultivation and planning to sell our Eloy facility to reduce debt. By refocusing on our high-performing Phoenix dispensaries and redeploying that capital into our Ohio expansion, we are aligning the business around our highest-return opportunities."As we move into 2026, our focus is on executing across our footprint - completing the Ohio retail build-out while maximising the efficiency of our Arizona retail operations. With a more focused operating model and continued disciplined capital allocation we believe Vext is well positioned to continue generating strong cash flow and driving long-term shareholder value in 2026 and beyond," added Mr. Offenberger.Summary of Recent AnnouncementsOn March 3, 2026, Vext announced that it has been granted a dual-use provisional license by the Ohio Division of Cannabis Control ("DCC") for a cannabis dispensary in Columbus, Ohio, marking Vext's seventh dispensary in the state, and second in Columbus.On March 30, 2026, the Company announced its intention to discontinue operations at its cultivation facility in Eloy, Arizona and pursue the sale of the same facility, as a part of its broader strategy focused on optimizing its Arizona footprint for profitability and return on capital, and supporting continued growth in Ohio.Q4 and Fiscal 2025 Financial Results Conference CallThe Company will host a conference call and webcast on April 29, 2026, at 08:00 am ET to discuss the financial results for the fourth quarter and full year 2025.Date: April 29, 2026 | Time: 8:00 am ET
Participant Dial-in: 1-833-752-3966 or 1-647-849-3159
Replay Dial-in: 1-855-669-9658 or 1-412-317-0088
Conference ID: 10207673
Playback #: 9521374 (Expires on May 13, 2026)
Listen to webcast: https://www.gowebcasting.com/14656Restatement of Prior Period Financial InformationDuring the preparation of its Fiscal 2025 financial statements, the Company identified the following items requiring restatement of previously reported financial information.Costs of Goods SoldThe Company reassessed its inventory valuation methodology to ensure alignment with IAS 2 Inventories. As a result of this reassessment, the Company adjusted amortization expense to reflect the capitalization of amortization related to cultivation and production licenses and adjusted general and administrative expenses to reflect expenses no longer capitalized. There was no change to total cost of goods sold due to offsetting amounts. The restatement reduced previously reported amortization expense for the year ended December 31, 2024 by $2.9 million (from $8.3 million to $5.5 million) and increased previously reported general and administrative expense by a corresponding $2.9 million (from $11.4 million to $14.3 million). The restatement had no impact on cash, revenue, gross profit, net loss, or earnings per share for any period.Prepaid AssetsThe Company determined that prepaid expenses and deposits of $5.6 million as at December 31, 2024 and $5.4 million as at December 31, 2023 relating to deposits paid in connection with the Big Perm Dispensaries acquisition should be reclassified from current assets to non-current assets, to better reflect their nature as deposits for a business combination. Total assets was unaffected by this reclassification. The restatement had no impact on cash, revenue, gross profit, net loss, or earnings per share for any period.Uncertain Tax Position and Income Tax PayableThe Company identified that certain uncertain tax position ("UTP") balances were understated in prior periods, resulting in the recognition of UTP liabilities of $5.5 million as of December 31, 2023 and $7.7 million as of December 31, 2024. Of the 2024 amount, $5.3 million was adjusted from income taxes payable and accrued liabilities. The net incremental $2.4 million was recorded as a reduction to opening retained earnings as of January 1, 2023. As of December 31, 2025, the UTP position was $8.1 million. The restatement had no impact on cash, revenue, gross profit, net loss, or earnings per share for any period. The increase from the prior estimate primarily reflects interest on periods not currently under IRS audit, resulting in a higher, non-recurring interest expense in Q4 2025. The UTP remains under audit and is subject to change. In light of the foregoing, the Company has restated financial information in its financial statements. For additional details, please refer to the Company's financial statements (including the notes thereto) and MD&A filed on SEDAR+.For more details, visit Vext's investor website or contact the IR team at investors@vextscience.com. Non-IFRS Financial MeasuresThis news release contains certain "non-IFRS financial measures" (equivalent to "non-GAAP financial measures", as such term is defined in National Instrument 52-112 - Non-GAAP and Other Financial Measures Disclosure ("NI 52-112")), "non-IFRS ratios" (equivalent to "non-GAAP ratios", as such term is defined in NI 52-112), or "supplementary financial measures" (as such term is defined in NI 52-112), which are described in further detail below. These financial measures do not have a standardized definition under IFRS, nor are they calculated or presented in accordance with IFRS and may not be comparable to similar measures presented by other companies. The Company has provided these financial measures as supplemental information and in addition to the financial measures that are calculated and presented in accordance with IFRS. The Company believes that these supplemental financial measures provide a valuable additional measure to use when analyzing the operating performance of the business. These supplemental financial measures should not be considered superior to, as a substitute for or as an alternative to, and should only be considered in conjunction with, the IFRS financial measures presented herein.The Company defines Cash Flow Margin by dividing Net cash provided by operating activities by Sales. The Company believes that this measure provides investors with insight into the Company's ability to generate cash from its revenue base. It is used by the Company to assess operating efficiency and liquidity performance without the impact of financing or investing activities. The calculation of Cash Flow Margin is as follows:

FY 2025

FY 2024

Q4 2025

Q3 2025

Q4 2024
Net cash provided by operating activities
(in thousands of US dollars)$11,712
$3,289
$3,196
$1,259
$4,016
Sales
(in thousands of US dollars)$51,367
$35,998
$13,728
$12,671
$10,194
Cash Flow Margin (%)
23%

9%

23%

10%

39%
 The Company defines EBITDA as earnings before interest, taxes, depreciation and amortization. The Company defines "Adjusted EBITDA" as net income (loss) from operations, as reported, before interest and tax, adjusted to exclude extraordinary items, non-recurring items, other non-cash items, including stock-based compensation expense, depreciation and amortization, foreign exchange and acquisition related costs, if applicable. The Company defines "Adjusted EBITDA Margin" as Adjusted EBITDA divided by Sales. The Company believes that these measures are useful financial metrics as they assist in determining the ability to generate cash from operations. Investors should be cautioned that EBITDA and Adjusted EBITDA should not be construed as an alternative to net earnings or cash flows as determined under IFRS. The reconciling items between net earnings, EBITDA, and Adjusted EBITDA are as follows:(in thousands of US dollars) 
FY 2025
 
FY 2024
 
Q4 2025
 
Q3 2025
 
Q4 2024
Sales $51,367
 $35,998
 $13,728
 $12,671
 $10,194
Net Income after taxes 
(17,994) 
(22,435) 
(10,557) 
(2,625) 
(9,215)Interest (Net) 
4,299
 
3,705
 
1,998
 
647
 
1,276
Income Taxes 
2,780
 
1,313
 
1,504
 
(243) 
2,020
Depreciation & Amortization 
15,876
 
15,177
 
4,019
 
4,006
 
3,872
EBITDA 
4,961
 
(2,240) 
(3,036) 
1,785
 
(2,047)Share (Profit) / Loss on JVs 
-
 
3,651
 
-
 
-
 
3,249
Share-based compensation 
47
 
695
 
(6) 
11
 
55
(Gain)/Loss on Asset Disposal 
-
 
146
 
-
 
-
 
143
Change in FV of debt 
(506) 
651
 
(514) 
846
 
(318)Loan costs EWB amortized 
-
 
177
 
-
 
-
 
44
Foreign Exchange 
8
 
(1) 
2
 
1
 
1
Change in FV of Biological  
1,947
 
2,543
 
903
 
(969) 
1,934
FV increment on acquired inventory sold  
-
 
1,323
 
-
 
-
 
-
Miscellaneous Income 
(548) 
(86) 
(311) 
(161) 
-
RSU Taxes 
-
 
181
 
-
 
-
 
177
Change in fair value of purchase option 
-
 
2,022
 
-
 
-
 
-
Goodwill and Intangible Impairment 
5,020
 
-
 
5,020
 
-
 
-
Adjusted EBITDA $10,930
 $9,062
 $2,058
 $1,513
 $3,238
Adjusted EBITDA Margin (%)* 
21%
 
25%
 
15%
 
12%
 
32%
 About Vext Science, Inc.Vext Science, Inc. is a U.S.-based cannabis operator with operations in Arizona and Ohio. Based out of Arizona, Vext owns and operates state-of-the-art cultivation facilities, fully built-out manufacturing facilities as well as dispensaries in both Arizona and Ohio. The Company manufactures Vapen™, one of the leading THC concentrates, edibles, and distillate cartridge brands in Arizona. Its selection of award-winning products are created with Vext's in-house, high-quality flower and distributed across Arizona and Ohio. Vext's leadership team brings a proven track record of building and operating profitable multi-state operations. The Company's primary focus is to continue growing in its core states of Arizona and Ohio, bringing together cutting-edge science, manufacturing, and marketing to provide a reliable and valuable customer experience while generating shareholder value. Vext Science, Inc. is listed on the Canadian Securities Exchange under the symbol VEXT and trades on the OTCQX market under the symbol VEXTF. Learn more at www.vextscience.com and connect with Vext on Twitter/X and LinkedIn.Forward-Looking Statements Statements in this news release that are forward-looking statements are subject to various risks and uncertainties concerning the specific factors disclosed here and elsewhere in Vext's periodic filings with Canadian securities regulators. When used in this news release, words such as "will, could, plan, estimate, expect, intend, may, potential, believe, should," and similar expressions, are forward-looking statements.Forward-looking statements may include, without limitation, statements regarding future developments and the business and operations of Vext, including but not limited to the Company's expansion in Ohio, its optimization strategy in Arizona and the anticipated results therefrom, the potential change to the Company's UTP position, the sale of the Eloy facility and the use of proceeds from such sale, the receipt of applicable regulatory approvals and the opening of additional dispensaries in Ohio, all of which are subject to the risk factors contained in Vext's continuous disclosure documents filed on SEDAR+ at www.sedarplus.ca. Although Vext has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking statements, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended, including, but not limited to: dependence on obtaining regulatory approvals; being engaged in activities currently considered illegal under U.S. Federal laws; change in laws; reliance on management; requirements for additional financing; competition; hindered market growth and state adoption due to inconsistent public opinion and perception of the medical-use and adult-use marijuana industry; and regulatory or political change. There can be no assurance that such information will prove to be accurate or that management's expectations or estimates of future developments, circumstances or results will materialize. Because of these risks and uncertainties, the results or events predicted in these forward-looking statements may differ materially from actual results or events.Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release are made as of the date of this release. Vext disclaims any intention or obligation to update or revise such information, except as required by applicable law, and Vext does not assume any liability for disclosure relating to any other company mentioned herein.The Canadian Securities Exchange has not reviewed, approved or disapproved the content of this news release.Eric Offenberger
Chief Executive Officer
844-211-3725For further information: Jonathan Ross, Vext Investor Relations
jon.ross @anajatwo-9851SOURCE: Vext Science, Inc.1 As a Tier 1 Cultivator, Vext has received approval under the Ohio Division of Cannabis Control's (DCC) 10(B) license program to develop three additional dual-use dispensaries, including Fairfield and Columbus, putting Vext on track to reach the state license cap of eight dispensaries by early 2027.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/294711
Original: Vext Reports Q4 and FY 2025; Fiscal 2025 Revenue up +43% to $51.4M, Operating Cash Flow up +256% to $11.7M as Ohio Retail Scales

Vext Announces Revised Date for Q4 and Fiscal 2025 Financial Results ReleaseApril 21, 2026 4:30 PM
NewsfileVancouver, British Columbia--(Newsfile Corp. - April 21, 2026) - Vext Science, Inc. (CSE: VEXT) (OTCQX: VEXTF) ("Vext" or the "Company") a U.S.-based cannabis operator in Arizona and Ohio, today announced that further to its previous disclosure regarding the timing of its fourth quarter and full year 2025 financial results release and conference call, the Company now expects to release its financial results for the period ended December 31, 2025, before market open on Wednesday, April 29, 2026. The Company will host a conference call and webcast on the same day at 08:00 am ET to discuss the financial results for the fourth quarter and full year 2025.CONFERENCE CALL DETAILSDate: April 29, 2026 | Time: 8:00 am ET
Participant Dial-in: 1-833-752-3966 or 1-647-849-3159
Replay Dial-in: 1-855-669-9658 or 1-412-317-0088
Conference ID: 10207673
Playback #: 9521374 (Expires on May 13, 2026)
Listen to webcast: https://www.gowebcasting.com/14656 A replay of the conference call and webcast will be available on Vext's investor website following the conclusion of the call.For more details, visit Vext's investor website or contact the IR team at investors@vextscience.com. About Vext Science, Inc.
Vext Science, Inc. is a U.S.-based cannabis operator with operations in Arizona and Ohio. Vext owns and operates state-of-the-art cultivation facilities, fully built-out manufacturing facilities as well as dispensaries across its footprint. The Company manufactures Vapen™, one of the leading THC concentrates, edibles, and distillate cartridge brands in Arizona. Its selection of award-winning products are created with Vext's in-house, high-quality flower and distributed across its key markets. Vext's leadership team brings a proven track record of building and operating profitable multi-state operations. The Company's primary focus is to continue growing in its core states of Arizona and Ohio, bringing together cutting-edge science, manufacturing, and marketing to provide a reliable and valuable customer experience while generating shareholder value. Vext Science, Inc. is listed on the Canadian Securities Exchange under the symbol VEXT and trades on the OTCQX market under the symbol VEXTF. Learn more at www.vextscience.com and connect with Vext on Twitter/X and LinkedIn.Forward-Looking Statements
Statements in this news release that are forward-looking statements are subject to various risks and uncertainties concerning the specific factors disclosed here and elsewhere in Vext's periodic filings with Canadian securities regulators. When used in this news release, words such as "will", "could", "plan", "estimate", "expect", "intend", "may", "potential", "believe", "should", "positioned", and similar expressions, are forward-looking statements.Forward-looking statements may include, without limitation, statements regarding the expected filing date of the financial results, future developments and the business and operations of the Vext, all of which are subject to the risk factors contained in Vext's continuous disclosure filed on SEDAR+ at www.sedarplus.ca. Although Vext has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking statements, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended, including, but not limited to: dependence on obtaining regulatory approvals; being engaged in activities currently considered illegal under U.S. Federal laws; change in laws; reliance on management; requirements for additional financing; competition; hindered market growth and state adoption due to inconsistent public opinion and perception of the medical-use and adult-use marijuana industry; and regulatory or political change. There can be no assurance that such information will prove to be accurate or that management's expectations or estimates of future developments, circumstances or results will materialize. Because of these risks and uncertainties, the results or events predicted in these forward-looking statements may differ materially from actual results or events.Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release are made as of the date of this release. Vext disclaims any intention or obligation to update or revise such information, except as required by applicable law, and Vext does not assume any liability for disclosure relating to any other company mentioned herein.The Canadian Securities Exchange has not reviewed, approved or disapproved the content of this news release.Eric Offenberger
Chief Executive Officer
844-211-3725For further information:
Jonathan Ross, Vext Investor Relations
jon.ross @anajatwo-9851SOURCE: Vext Science, Inc.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/293454
Original: Vext Announces Revised Date for Q4 and Fiscal 2025 Financial Results Release

Vext Science Announces Strategic Optimization of Arizona Operations and Plans for Ohio Cultivation ExpansionMarch 30, 2026 7:30 AM
NewsfileStrategic closure and planned sale of Eloy cultivation facility expected to improve Arizona profitability and enhance free cash flow.Proceeds from the sale to facilitate debt reduction, with key equipment redeployed to the Ohio market, saving approximately $2 million in capital expenditures to support Vext's build-out in the State. Plans to seek approval to expand Jackson cultivation to support a growing retail footprint as Ohio adult-use sales surpass $1 billion in the first full year1.Vext to release financial results for Q4 and Fiscal 2025 on April 23, 2026; Conference call on April 23, 2026 at 8am ET. Vancouver, British Columbia--(Newsfile Corp. - March 30, 2026) - Vext Science, Inc. (CSE: VEXT) (OTCQX: VEXTF) ("Vext" or the "Company") a U.S.-based cannabis operator in Arizona and Ohio, today announced its intention to discontinue operations at its cultivation facility in Eloy, Arizona (the "Eloy Facility") and pursue the sale of the Eloy Facility, as a part of its broader strategy focused on optimizing its Arizona footprint for profitability and return on capital, and supporting continued growth in Ohio. All currency references used in this news release are in U.S. currency unless otherwise noted."The planned closure of our Eloy facility and its subsequent potential sale reflects our commitment to disciplined capital allocation while prioritizing high-growth opportunities," said Eric Offenberger, CEO of Vext. "Arizona remains an important market for Vext, but persistent state-wide oversupply and recent market contraction necessitate a leaner, more efficient footprint to maintain and grow profitability. By transitioning away from internal cultivation at Eloy, we can take advantage of favorable wholesale market conditions while maintaining a reliable supply of high-quality product for our retail network. This shift will enable us to proactively address market headwinds, reduce debt, and improve profitability without compromising the customer experience. At the same time, we are redeploying capital and assets to Ohio, where the market continues to demonstrate strong growth following the transition to adult-use sales. As we approach the state's retail cap, we intend to seek approval to expand our Jackson cultivation facility to support our growing vertically integrated footprint and long-term plans in the state," added Mr. Offenberger.Arizona Operations OptimizationThe Arizona cannabis market continues to face significant oversupply and pricing pressure, despite several operators exiting the market in recent years. Statewide cannabis sales declined approximately 9% year-over-year in 20252. Despite multiple years of revenue declines across the state, Vext has maintained performance above industry averages and positive adjusted EBITDA through disciplined upstream operations, a retail-focused model, and tight cost control throughout the network.The Company's strategic decision to close the Eloy Facility reflects its disciplined approach to capital allocation. Management has consistently identified and executed optimization initiatives across its asset base in response to evolving market conditions, including the sale of the Company's Prescott Valley facility in November 2023. The planned closure and sale of the Eloy Facility continues this proactive approach, designed to prioritize the creation of sustainable long-term shareholder value. Ohio Cultivation ExpansionVext intends to seek approval from the State of Ohio to expand its cultivation facility in Jackson, positioning the Company to support the continued growth of its vertically integrated footprint in the state. Ohio represents a key growth market following the transition to adult-use cannabis sales, with statewide sales surpassing $1 billion in the first full year of adult-use1. Vext currently operates five consolidated dispensaries in Ohio and holds eight retail licenses, the state's current ownership cap. The Company's sixth location is expected to open in the second quarter of 2026, with its seventh location currently under construction. Construction on the eighth and final location is anticipated to begin in the third quarter of 2026. The planned cultivation expansion is expected to support new dispensaries expected to come online in 2026 and 2027, increasing demand across the Company's Ohio retail network. Expected Operational and Financial ImprovementsThe transition is expected to improve Arizona adjusted EBITDA margins, driven by the elimination of high fixed-cost indoor cultivation operations and a shift to a more flexible, market-responsive supply model.The Company expects a significant improvement in its cash conversion cycle, transitioning from an approximately 100-day seed-to-sale cultivation model to a streamlined procurement and sell-through model, reducing working capital requirements and improving operating cash flow.The closure eliminates ongoing fixed labor, overhead, and facility operating costs associated with the Eloy cultivation operation.Net proceeds from the sale of the Eloy building will be applied directly to reduce outstanding mortgage debt, lowering the Company's interest costs on a go-forward basis.Capital Expenditure SavingsSubject to applicable regulatory approval, equipment from the Eloy Facility will be redeployed to support the planned cultivation expansion at the Company's Jackson, Ohio facility, avoiding the need for new capital investment of approximately $2 million to equip that build-out.The divestiture of the Eloy facility eliminates future maintenance capital expenditure requirements associated with sustaining a scaled indoor cultivation operation, including ongoing reinvestment in HVAC, lighting, irrigation, and growing infrastructure.Vext's Arizona retail operations will be supplied through the wholesale market, which the Company expects to offer a lower cost of supply for the foreseeable future. The Phoenix facility retains manufacturing and processing, along with cultivation infrastructure, preserving the ability to resume internal production quickly should market conditions change. The Eloy Facility is expected to be decommissioned by the end of the second quarter of 2026, and the building will be marketed for sale. Financial Results for Q4 and Fiscal 2025 on April 23, 2026Vext plans to release its financial results for the period ended December 31, 2025, before market open on Thursday, April 23, 2026. The Company will host a conference call and webcast on the same day at 08:00 am ET to discuss the financial results for the fourth quarter and full year 2025.CONFERENCE CALL DETAILSDate: April 23, 2026 | Time: 8:00 am ET
Participant Dial-in: 1-833-752-3966 or 1-647-849-3159
Replay Dial-in: 1-855-669-9658 or 1-412-317-0088
Conference ID: 10207673
Playback #: 9521374 (Expires on May 7, 2026)
Listen to webcast: https://www.gowebcasting.com/14656A replay of the conference call and webcast will be available on Vext's investor website following the conclusion of the call.For more details, visit Vext's investor website or contact the IR team at investors@vextscience.com. About Vext Science, Inc.Vext Science, Inc. is a U.S.-based cannabis operator with operations in Arizona and Ohio. Vext owns and operates state-of-the-art cultivation facilities, fully built-out manufacturing facilities as well as dispensaries across its footprint. The Company manufactures Vapen™, one of the leading THC concentrates, edibles, and distillate cartridge brands in Arizona. Its selection of award-winning products are created with Vext's in-house, high-quality flower and distributed across its key markets. Vext's leadership team brings a proven track record of building and operating profitable multi-state operations. The Company's primary focus is to continue growing in its core states of Arizona and Ohio, bringing together cutting-edge science, manufacturing, and marketing to provide a reliable and valuable customer experience while generating shareholder value. Vext Science, Inc. is listed on the Canadian Securities Exchange under the symbol VEXT and trades on the OTCQX market under the symbol VEXTF. Learn more at www.vextscience.com and connect with Vext on Twitter/X and LinkedIn.Forward-Looking Statements
Statements in this news release that are forward-looking statements are subject to various risks and uncertainties concerning the specific factors disclosed here and elsewhere in Vext's periodic filings with Canadian securities regulators. When used in this news release, words such as "will", "could", "plan", "estimate", "expect", "intend", "may", "potential", "believe", "should", "positioned", and similar expressions, are forward-looking statements.Forward-looking statements may include, without limitation, statements regarding future developments and the business and operations of Vext, including but not limited to the Company's decommissioning and planned sale of the Eloy Facility, its expansion in Ohio and the anticipated results therefrom, the use of proceeds from a sale of the Eloy Facility, the receipt of applicable regulatory approvals, the expected filing date of the financial results, and the development and opening of additional dispensaries in Ohio, all of which are subject to the risk factors contained in Vext's continuous disclosure filed on SEDAR+ at www.sedarplus.ca. Although Vext has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking statements, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended, including, but not limited to: dependence on obtaining regulatory approvals; being engaged in activities currently considered illegal under U.S. Federal laws; change in laws; reliance on management; requirements for additional financing; competition; hindered market growth and state adoption due to inconsistent public opinion and perception of the medical-use and adult-use marijuana industry; and regulatory or political change. There can be no assurance that such information will prove to be accurate or that management's expectations or estimates of future developments, circumstances or results will materialize. Because of these risks and uncertainties, the results or events predicted in these forward-looking statements may differ materially from actual results or events.Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release are made as of the date of this release. Vext disclaims any intention or obligation to update or revise such information, except as required by applicable law, and Vext does not assume any liability for disclosure relating to any other company mentioned herein.The Canadian Securities Exchange has not reviewed, approved or disapproved the content of this news release.Eric Offenberger
Chief Executive Officer
844-211-3725For further information:
Jonathan Ross, Vext Investor Relationsjon.ross @anajatwo-9851SOURCE: Vext Science, Inc.1 Ohio Department of Commerce
2 Arizona Department of RevenueTo view the source version of this press release, please visit https://www.newsfilecorp.com/release/290347
Original: Vext Science Announces Strategic Optimization of Arizona Operations and Plans for Ohio Cultivation Expansion

Vext Advances Ohio Expansion with Seventh Retail LocationMarch 3, 2026 5:00 PM
NewsfileSecures provisional dual-use license for Columbus dispensary, with operations expected to begin in Q4 2026, subject to regulatory approvals.Marks Vext's seventh dispensary in Ohio, and second in Columbus, as the Company advances toward the state's eight-store cap.Scales vertically integrated footprint in Ohio, positioning Vext to drive operating leverage and cash flow growth as additional retail locations come online and stabilize.Vancouver, British Columbia--(Newsfile Corp. - March 3, 2026) - Vext Science, Inc. (CSE: VEXT) (OTCQX: VEXTF) ("Vext" or the "Company") a U.S.-based cannabis operator with vertical operations in Arizona and Ohio, today announced that it has been granted a dual-use provisional license by the Ohio Division of Cannabis Control ("DCC") for a cannabis dispensary in Columbus, Ohio (the "Dispensary"). All currency references used in this news release are in U.S. currency unless otherwise noted.The Dispensary will be located on the west side of Columbus, near the I-270 and Roberts Road interchange, providing strong visibility from the city's primary beltway and convenient access within Ohio's largest cannabis market. The site sits adjacent to Hilliard and serves a growing residential area with limited nearby cannabis retail locations. The Dispensary will represent Vext's second location in Columbus. The provisional license confirms the Dispensary complies with all applicable zoning and statutory setback requirements for both medical and adult-use retail sales. The Company has secured all required construction permits and executed a construction agreement for the build-out of a new standalone facility, including a drive-thru. Construction is expected to begin in March, with operations expected to commence in the fourth quarter of 2026, subject to regulatory approvals. Total capital costs are expected to be approximately $3.3 million, including land acquisition and construction.Eric Offenberger, CEO of Vext commented, "Securing our seventh Ohio dispensary license is another important step in our disciplined retail expansion. Columbus is the state's largest cannabis market, and this high-visibility location near I-270 gives us access to a growing residential area with limited nearby competition. With five consolidated dispensaries currently operating in Ohio and our sixth location in Fairfield expected to open in Q2 of 2026, which given its location has the potential to become one of our strongest performing stores, we're building from a position of strength. Each new store extends the leverage of our vertically integrated platform and reinforces our margin and cash flow trajectory. With construction underway and our remaining Ohio projects advancing, we have a clear line of sight to the state's eight-store cap and remain committed to disciplined capital allocation and sustainable shareholder value creation."Across the Company's three remaining Ohio locations, Vext is working closely with local zoning authorities and regulators to progress permitting and construction and to maintain project timelines. Upon completion, the Company will operate the state maximum of eight dispensaries, supported by its Tier I cultivation and manufacturing facilities.Vext's Current Footprint in Ohio:Facility1StatusTier 1 Cultivation Facility – 25,000 square feet (Jackson, Ohio)Fully operational. Ability to expand to 50,000 square feet. Certificate of Operation received for adult-use.Manufacturing Facility (Jackson, Ohio)Fully operational.Herbal Wellness Center (Jackson, Ohio)Fully operational as a medical and adult-use dispensary.Herbal Wellness Center (Columbus, Ohio)Fully operational as a medical and adult-use dispensary.Herbal Wellness Center (Athens, Ohio)Fully operational as a medical and adult-use dispensary.Herbal Wellness Center (Jeffersonville, Ohio)Fully operational as a medical and adult-use dispensary.Dispensary 5 (Portsmouth, Ohio)Fully operational as a medical and adult-use dispensary.Dispensary 6 (Fairfield, Ohio)Provisional dual-use license received and construction is in process. Expected to be operational by Q2 2026.Dispensary 7 (Columbus, Ohio)Provisional dual-use license received and construction expected to commence in March 2026. Expected to be operational by Q4 2026.Dispensary 8
(Granted approval to develop 1 additional dual-use dispensary)As a Tier 1 Cultivator, Vext has received approval under the DCC's 10(B) license program to develop three dual-use dispensaries, including Dispensaries 6 and 7. The target location for the remaining dispensary has been identified and will be announced when provisional permits are issued by the DCC. For more details, visit Vext's investor website or contact the IR team at investors@vextscience.com. About Vext Science, Inc.
Vext Science, Inc. is a U.S.-based cannabis operator with vertical operations in Arizona and Ohio. Vext's expertise spans from cultivation through to retail operations in its key markets. Based out of Arizona, Vext owns and operates state-of-the-art cultivation facilities, fully built-out manufacturing facilities as well as dispensaries in both Arizona and Ohio. The Company manufactures Vapen™, one of the leading THC concentrates, edibles, and distillate cartridge brands in Arizona. Its selection of award-winning products are created with Vext's in-house, high-quality flower and distributed across Arizona and Ohio. Vext's leadership team brings a proven track record of building and operating profitable multi-state operations. The Company's primary focus is to continue growing in its core states of Arizona and Ohio, bringing together cutting-edge science, manufacturing, and marketing to provide a reliable and valuable customer experience while generating shareholder value. Vext Science, Inc. is listed on the Canadian Securities Exchange under the symbol VEXT and trades on the OTCQX market under the symbol VEXTF. Learn more at www.vextscience.com and connect with Vext on Twitter/X and LinkedIn.Forward-Looking Statements
Statements in this news release that are forward-looking statements are subject to various risks and uncertainties concerning the specific factors disclosed here and elsewhere in Vext's periodic filings with Canadian securities regulators. When used in this news release, words such as "will", "could", "plan", "estimate", "expect", "intend", "may", "potential", "believe", "should", "positioned", and similar expressions, are forward-looking statements.Forward-looking statements may include, without limitation, statements regarding future developments and the business and operations of Vext, including but not limited to the Company's expansion in Ohio and the anticipated results therefrom, the receipt of applicable regulatory approvals, the acquisition of additional licenses, and the development and opening of additional dispensaries in Ohio, all of which are subject to the risk factors contained in Vext's continuous disclosure filed on SEDAR+ at www.sedarplus.ca. Although Vext has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking statements, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended, including, but not limited to: dependence on obtaining regulatory approvals; being engaged in activities currently considered illegal under U.S. Federal laws; change in laws; reliance on management; requirements for additional financing; competition; hindered market growth and state adoption due to inconsistent public opinion and perception of the medical-use and adult-use marijuana industry; and regulatory or political change. There can be no assurance that such information will prove to be accurate or that management's expectations or estimates of future developments, circumstances or results will materialize. Because of these risks and uncertainties, the results or events predicted in these forward-looking statements may differ materially from actual results or events.Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release are made as of the date of this release. Vext disclaims any intention or obligation to update or revise such information, except as required by applicable law, and Vext does not assume any liability for disclosure relating to any other company mentioned herein.The Canadian Securities Exchange has not reviewed, approved or disapproved the content of this news release.Eric Offenberger
Chief Executive Officer
844-211-3725For further information:
Jonathan Ross, Vext Investor Relations
jon.ross @anajatwo-9851SOURCE: Vext Science, Inc.1 As a Tier 1 Cultivator, Vext has received approval under the Ohio Division of Cannabis Control's (DCC) 10(B) license program to develop three additional dual-use dispensaries, including Fairfield, putting Vext on track to reach the state license cap of eight dispensaries in 2026.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/286113
Original: Vext Advances Ohio Expansion with Seventh Retail Location

Amen. Soon enough the cat will be out of the bag. Until then, I slowly add. See you @ $5.

I've been in this stock for a few months now. Never seen a penny stock with such great (and AUDITED) financials. Surprised it hasn't caught on here but it just means more cheap shares for us.

Where is everyone? +20% today. Hasn't even started the real move yet. Low float with insiders owning around 45%. See you at $10 next year sometime.

Mark this post. I am in heavy. Purchased yesterday and took the reigns as a Moderator. Should be a very successful 2021. Come on board for this soon to be wild ride.

Holding share price on very little volume. Impressive. Someone please sell me some cheapies before EOY :)

You might be waiting for awhile. I would be shocked if this company wasn't bought out within the next 6 months. Financials are great

Still waiting. Nobody wants to sell me any at .60.

Getting primed for 2021 and Arizona's recreational marijuana law to kick in!

Can someone please sell me a few shares here. I'm looking for a Pre-Christmas discount. -Sincerely, Me.

Vext Science Welcomes Arizona Approval of Legalized Possession of Marijuana for Adult Use

https://www.newswire.ca/news-releases/vext-science-welcomes-arizona-approval-of-legalized-possession-of-marijuana-for-adult-use-826208471.html

Let’s goooo back to $1

Bring on Arizona rec market , vector q will triple ... imho

VAPNF: effective Nov. 12,2019 Vapen MJ Ventures Corp., VAPNF, will change to Vext Science Inc., VEXTF:

https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes

VMVCF changed to VAPNF:

https://otce.finra.org/otce/dailyList?viewType=Symbol%2FName%20Changes

March 31st, 2019

Weighted average number of common shares outstanding 75,054,661

3 Premium Cannabis Brands Capitalizing On The Nevada Market

June 26, 2019
BY ANTHONY VARRELL

2019 has been a banner year for the US cannabis industry and has been highlighted by massive acquisitions and cross-country expansions. The recent developments have been significant, and we have been favorable on the way the US cannabis industry has advanced. The recent advancements have been beneficial for the companies that are levered to the US market and this is a trend that we expect to continue.

Over the next year, we expect to see further consolidation as the US cannabis market continues to become a more significant opportunity. Earlier this month, we visited Las Vegas and continue to be impressed by this cannabis market. One of the primary reasons for us being so favorable on the Las Vegas opportunity is due to the more than 42 million tourists that visit the city on an annual basis.

When a company is working to build a national (or global) brand, they need to be focused on several key markets. These markets are similar in the way that they attract tourists and bring the people to the brand. We are favorable on this strategy and believe it is a cost-effective strategy for a company that is trying to reach the largest possible markets.

One of the reasons why we are favorable on this strategy is because these tourists return home and remember the brands they came across. This creates a great opportunity for these brands once they enter the markets where these tourists live and believe that the Las Vegas market is the best market for accomplishing this goal for the cannabis industry.

We have been bullish on the Las Vegas cannabis market and this is an opportunity that we continue to closely monitor. Today, we want to highlight 3 cannabis companies that are levered to the Las Vegas cannabis opportunity and have been working to expand its position in the US market.

Vapen MJ Ventures: Expanding its Position on the West Coast

Vapen MJ Ventures (VAPN.CN) is a cannabis company that we have been excited about and continue to monitor. Last week, the company announced a letter of intent with Pegasus to establish a partnership for the production and extraction of cannabis in Las Vegas, Nevada. Demand for cannabis concentrates continues to increase and this is a trend that we have been especially excited about.

Through this partnership, Vapen will be able to create significant brand awareness and are favorable on the growth prospects associated with this relationship (which is expected to be get started in the next 30 days). This operation is expected to commence in the fall and the product line is expected to include cannabis extracts (vape pens and concentrates) and cannabis infused products (i.e. candies, gummies, chocolate bars).

One of the reasons we are favorable on this partnership is related to what each company brings to the relationship. Vapen will provide management services and standard operating procedures for production and extraction. The company will also be responsible for the bulk extraction for other brands. Pegasus and their partners are supplying funding for the equipment, working capital, and biomass. We expect this relationship to start generating significant revenues late in 2019 and will monitor how the team is able to execute on this.

Vapen is a proven operator and has created a leading medical cannabis concentrate brand in Arizona with distribution to more than 100+ dispensaries in the state. Arizona is the third largest medical cannabis market in the US and we are favorable on the company’s ability to capitalize on this burgeoning opportunity. If recreational cannabis is legalized in Arizona, it should prove to be a major catalyst for companies like Vapen and this is something that we are excited about.

We believe that Vapen has several major potential catalysts for growth and find this to be significant. The company is led by a management team with a proven track record of success and that is laser focused on expanding its reach. Vapen offers a premium product line and has leverage to some of the most attractive verticals of the cannabis industry. We are favorable on the move into Nevada and expect to see the company enter new markets in the near future. Vapen represents an exciting opportunity and one that we will continue to be watching.

1933 Industries: An Emerging CBD and THC Opportunity

Earlier this month, we visited 1933 Industries (TGIF: CSE) (TGIFF: OTCQB) while visiting Las Vegas and this is an opportunity that we are excited about. In the very near future, the company will be moving into a much larger facility and this is expected to have a massive impact on the amount of revenue that can be generated.

One of the reasons we are very excited about this opportunity is related to the brands that are owned by 1933 Industries. The company is comprised of three distinct brands: Alternative Medicine Association (AMA), Canna Hemp, and Denver Dab Company (DDC). These brands are levered to both the cannabidiol (CBD) and tetrahydrocannabinol (THC) opportunity and have been generating significant traction.

While AMA and DDC have attractive leverage to the THC opportunity, Canna Hemp is highly levered to the cannabidiol (CBD) opportunity and we believe that this is one of the most attractive aspects of the business. During the last year, Canna Hemp has gained significant traction and the products are now being carried by more than 600 retail stores across the US.

Demand for the company’s THC and CBD products continues to increase and this is an important part of the story. Once the new facility becomes operational, 1933 Industries should see its production capacity increase ten-fold and will result in the production of much more company-branded products. We expect this facility to come on-line in the near future and this should be a major catalyst for the business.

Although 1933 Industries has massive potential catalysts for growth, the shares have been under pressure and have been trading lower with the overall cannabis sector over the last few months. We believe this pullback is overdone and believe that the valuation is very attractive after this move lower. Based on the potential revenue that can be created through the new facility, the risk-reward scenario is attractive, and we are excited about this opportunity.

Ionic Brands: An Emerging US Cannabis Branding Play

Last month, we highlighted Ionic Brands (IONC: CNX) (ZRRRF: OTC) which has been able to penetrate some of the most competitive cannabis markets by accumulating a portfolio of leading cannabis brands. When it comes to the branding opportunity for cannabis products, we believe that Ionic Brands has had its finger on the pulse of the cannabis market and this is an opportunity to be watching.

When it comes to the Las Vegas opportunity, Ionic Brands has significant leverage to this burgeoning market and recently completed the previously announced acquisition of Vegas Valley Growers North (VVG), a vertically-integrated cannabis business that has been generating significant cash flow and is expected to generate approx. $6.6 million of revenue in 2019. One of the reasons we are favorable on the acquisition of VVG is due to the amount of synergies that can be found between the businesses. Another reason we are excited about this transaction is related to the amount of exposure that will be created for Ionic’s portfolio of premium cannabis brands with domestic and international cannabis consumers.

VVG’s flagship product is the Vegas M Stick and the Reno M Stick branded vape pens which have distribution into more than 75% of the dispensaries in Nevada and we find this to be significant. The acquisition of VVG also includes four state licenses for the cultivation and manufacturing of both medical and recreational cannabis. The company expects to be granted the medical and recreational cannabis distribution licenses in the near future and this should be a catalyst for the entire business.

When looking at VVG, of the most exciting aspects of the story is related to the expansion opportunity. Currently, VVG operates a 1,700 sq. ft. production facility and is the process of building a 60,000 sq. ft. manufacturing facility that is expected to completed in the third quarter of 2019. VVG is also planning to construct an 80,000 sq. ft. facility in the fourth quarter of 2019 and we find this to be significant. One the expansion is complete, VVG will be one of the largest cannabis producers in Nevada and we will monitor how the team executes on this.

Later this year, we expect to see several Ionic branded products added to VVG’s existing distribution pipeline and are bullish on the growth prospects associated with this. The company expects to increase sales of Ionic branded products by leveraging off VVG’s existing distribution pipeline and by introducing a variety of Ionic branded products to this distribution channel. Over the next year, we expect the Nevada market to prove to be a major growth driver for Ionic Brands and believe that the market underappreciates the growth prospects associated with this.